|
GILD | Gilead Sciences, Inc. |
|
|
GILD | Gilead Sciences, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.15 |
| Leverage | 67.23% |
| Market Cap | $ 129.7B |
| PE | 293.77 |
| Dividend Yield | 3.05% |
| Profit | $ 441.4m |
| Margin | 1.54% |
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.